G. Steven Burrill is CEO of Burrill & Company, a San Francisco based life sciences merchant bank with over $500 million under management. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50).
He currently serves as Chairman of the Boards of Icoria (NASDAQ: ICOR), Pharmasset, and Pyxis Genomics; and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (Amex: DMI), Galapagos Genomics, Targacept, and Third Wave Technologies (NASDAQ: TWTI).
Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm’s services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.
